BEIJING, Jan. 23, 2024 -- CASI Pharmaceuticals Inc. (Nasdaq: CASI), a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, is thrilled to announce a significant strategic partnership with China National Medicines Corporation Ltd. (CNMC). This collaboration marks a milestone in CASI's commercialization efforts, granting CNMC the exclusive distribution rights for CASI's newly launched product, FOLOTYN^® (Pralatrexate), for the treatment of Peripheral T-Cell Lymphoma (PTCL) in China.

FOLOTYN^® has shown promising efficacy and safety profiles in clinical trials. Its introduction to the Chinese market reflects CASI's commitment to addressing unmet medical needs and improving the lives of patients suffering from this challenging and life-threatening form of diseases.

The signing ceremony, held on Jan. 23, 2023, was a landmark event for both organizations. It was attended by Larry Zhang, Global President of CASI, and Guotao Tian, General Manager of CNMC, alongside other esteemed representatives from both companies. The partnership underscores both CASI's and CNMC's dedication to bringing advanced therapeutic options to patients in China.

"We are thrilled to partner with CNMC, an esteemed leader in the pharmaceutical distribution sector in China," said Larry Zhang, Global President of CASI. "This partnership is a testament to CASI's strategy and our commitment to make FOLOTYN^® available to PTCL patients in need across China. We are confident that CNMC's robust distribution network and deep market knowledge will be instrumental in the success of Folotyn^® in this vital market."

Guotao Tian, General Manager of CNMC, also expressed his enthusiasm for the partnership, stating, "CNMC is proud to collaborate with CASI, a company renowned for its innovative approaches in hematology oncology. We are committed to leveraging our distribution capabilities to ensure that FOLOTYN^® is accessible to healthcare providers and patients throughout China. This is a significant step in our mission to enrich the lives of patients with advanced medical treatments."

The strategic partnership between CASI Pharmaceuticals and CNMC is poised to have a substantial impact on the treatment landscape for PTCL in China, providing a new ray of hope for patients and families affected by this disease.

About CASI Pharmaceuticals

CASI Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is focused on acquiring, developing, and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. The Company intends to execute its plan to become a leader by launching medicines in the greater China market, leveraging the Company's China-based regulatory and commercial competencies and its global drug development expertise. The Company's operations in China are conducted through its wholly owned subsidiary, CASI Pharmaceuticals (China) Co., Ltd., located in Beijing, China. More information on CASI is available at www.casipharmaceuticals.com.
 

About China National Medicines Corporation Ltd.

CNMC specializes in the Beijing market and extends its reach nationwide. Focusing on pharmaceutical and medical device distribution services as its core business, CNMC positions itself in several key segments: regional medical direct sales, national pharmaceutical distribution, sales of narcotic and psychotropic medications, and specialized pharmaceutical industries. The company concentrates on six distinctive business areas: dental services, professional retail, diagnostic reagents, logistics services, marketing services, and medical services. By establishing a platform for an integrated 'Specialty + Healthcare Ecosystem,' CNMC aims to become a leader in China's unique pharmaceutical industry. Adhering to the philosophy of "Protecting Life, Caring for Health," the company serves the national pharmaceutical industry's endpoints and patients with dedication and expertise.